ID1.AU Identifai Genetics Limited
- Market cap
- AUD 67.2M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is ID1.AU undervalued?
Graham numberThe Graham number of Identifai Genetics Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Identifai Genetics Limited fundamental analysis
No fundamental analysis for Identifai Genetics Limited yet.
Identifai Genetics Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Identifai Genetics Limited
Identifai Genetics Limited provides prenatal genetic screening through the application of genome-wide sequencing and artificial intelligence in Israel, the United States, Hong Kong, China, and Australia. The company's product, Windrose, is a first-trimester non-invasive prenatal test that provides cfDNA-based fetal risk assessment for more than 280 clinically actionable genes, all from a single blood draw and without requiring a partner sample. The company was founded in 202…
Full company profileFinancial statements of Identifai Genetics Limited are not available yet.
Identifai Genetics Limited dividends
Identifai Genetics Limited has not paid dividends in the last 1 fiscal years.
Who owns Identifai Genetics Limited
- Insiders 55.12%
- Institutions 0.92%
- Public & others 43.96%
- Shares outstanding 192M
- Free float 70.0M
Identifai Genetics Limited company profile
- Company name
- Identifai Genetics Limited
- Ticker
- ID1.AU
- ISIN
- AU0000488983
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Fiscal year end
- December
- Address
- 295 Rokeby Road, Subiaco, WA, Australia, 6008
- Phone
- 61 8 6555 2950
- Website
- identifai-genetics.com
About Identifai Genetics Limited
Identifai Genetics Limited provides prenatal genetic screening through the application of genome-wide sequencing and artificial intelligence in Israel, the United States, Hong Kong, China, and Australia. The company's product, Windrose, is a first-trimester non-invasive prenatal test that provides cfDNA-based fetal risk assessment for more than 280 clinically actionable genes, all from a single blood draw and without requiring a partner sample. The company was founded in 2021 and is based in Subiaco, Australia.
Identifai Genetics Limited management
4- Mr. Eyal MillerChief Executive Officer
- Oren TadmorHead of Product & Co-founder
- Gilad MagnaziChief Operating Officer
- Prof. Noam Shomron Ph.D.C.S.O